312 related articles for article (PubMed ID: 22808058)
1. Hepcidin-25 in chronic hemodialysis patients is related to residual kidney function and not to treatment with erythropoiesis stimulating agents.
van der Weerd NC; Grooteman MP; Bots ML; van den Dorpel MA; den Hoedt CH; Mazairac AH; Nubé MJ; Penne EL; Gaillard CA; Wetzels JF; Wiegerinck ET; Swinkels DW; Blankestijn PJ; Ter Wee PM;
PLoS One; 2012; 7(7):e39783. PubMed ID: 22808058
[TBL] [Abstract][Full Text] [Related]
2. Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.
Tessitore N; Girelli D; Campostrini N; Bedogna V; Pietro Solero G; Castagna A; Melilli E; Mantovani W; De Matteis G; Olivieri O; Poli A; Lupo A
Nephrol Dial Transplant; 2010 Dec; 25(12):3996-4002. PubMed ID: 20538788
[TBL] [Abstract][Full Text] [Related]
3. Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis.
Honda H; Kobayashi Y; Onuma S; Shibagaki K; Yuza T; Hirao K; Yamamoto T; Tomosugi N; Shibata T
PLoS One; 2016; 11(3):e0151601. PubMed ID: 26978524
[TBL] [Abstract][Full Text] [Related]
4. HFE mutations modulate the effect of iron on serum hepcidin-25 in chronic hemodialysis patients.
Valenti L; Girelli D; Valenti GF; Castagna A; Como G; Campostrini N; Rametta R; Dongiovanni P; Messa P; Fargion S
Clin J Am Soc Nephrol; 2009 Aug; 4(8):1331-7. PubMed ID: 19541813
[TBL] [Abstract][Full Text] [Related]
5. Hepcidin and diabetes are independently related with soluble transferrin receptor levels in chronic dialysis patients.
Belo L; Rocha S; Valente MJ; Coimbra S; Catarino C; Bronze-da-Rocha E; Rocha-Pereira P; do Sameiro-Faria M; Oliveira JG; Madureira J; Fernandes JC; Miranda V; Santos-Silva A
Ren Fail; 2019 Nov; 41(1):662-672. PubMed ID: 31296086
[No Abstract] [Full Text] [Related]
6. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
7. Reduction of serum hepcidin by hemodialysis in pediatric and adult patients.
Zaritsky J; Young B; Gales B; Wang HJ; Rastogi A; Westerman M; Nemeth E; Ganz T; Salusky IB
Clin J Am Soc Nephrol; 2010 Jun; 5(6):1010-4. PubMed ID: 20299375
[TBL] [Abstract][Full Text] [Related]
8. Medium cut-off dialyzer improves erythropoiesis stimulating agent resistance in a hepcidin-independent manner in maintenance hemodialysis patients: results from a randomized controlled trial.
Lim JH; Jeon Y; Yook JM; Choi SY; Jung HY; Choi JY; Park SH; Kim CD; Kim YL; Cho JH
Sci Rep; 2020 Sep; 10(1):16062. PubMed ID: 32994531
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients.
Yılmaz I; Ozkok A; Kostek O; Kolukısa A; Duran I; Odabaş AR; Kemal Işman F; Işbilen Başok B
Ren Fail; 2016; 38(1):89-95. PubMed ID: 26539647
[TBL] [Abstract][Full Text] [Related]
10. Hepcidin--a potential novel biomarker for iron status in chronic kidney disease.
Zaritsky J; Young B; Wang HJ; Westerman M; Olbina G; Nemeth E; Ganz T; Rivera S; Nissenson AR; Salusky IB
Clin J Am Soc Nephrol; 2009 Jun; 4(6):1051-6. PubMed ID: 19406957
[TBL] [Abstract][Full Text] [Related]
11. Hepcidin and regulation of iron homeostasis in maintenance hemodialysis patients.
Sany D; Elsawy AE; Elshahawy Y
Saudi J Kidney Dis Transpl; 2014 Sep; 25(5):967-73. PubMed ID: 25193892
[TBL] [Abstract][Full Text] [Related]
12. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
[TBL] [Abstract][Full Text] [Related]
13. Impact of serum hepcidin and inflammatory markers on resistance to erythropoiesis-stimulating therapy in haemodialysis patients.
El Sewefy DA; Farweez BA; Behairy MA; Yassin NR
Int Urol Nephrol; 2019 Feb; 51(2):325-334. PubMed ID: 30600440
[TBL] [Abstract][Full Text] [Related]
14. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
15. Serum hepcidin in haemodialysis patients: associations with iron status and microinflammation.
Xu Y; Ding XQ; Zou JZ; Liu ZH; Jiang SH; Chen YM
J Int Med Res; 2011; 39(5):1961-7. PubMed ID: 22118000
[TBL] [Abstract][Full Text] [Related]
16. Effect of increased blood flow rate on renal anemia and hepcidin concentration in hemodialysis patients.
Yamamoto M; Matsumoto T; Ohmori H; Takemoto M; Ikeda M; Sumimoto R; Kobayashi T; Kato A; Ohdan H
BMC Nephrol; 2021 Jun; 22(1):221. PubMed ID: 34126941
[TBL] [Abstract][Full Text] [Related]
17. Serum hepcidin levels in patients with end-stage renal disease on hemodialysis.
Rubab Z; Amin H; Abbas K; Hussain S; Ullah MI; Mohsin S
Saudi J Kidney Dis Transpl; 2015 Jan; 26(1):19-25. PubMed ID: 25579711
[TBL] [Abstract][Full Text] [Related]
18. Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.
Gummer J; Trengove R; Pascoe EM; Badve SV; Cass A; Clarke P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Johnson DW; Olynyk JK; Ferrari P;
Nephrology (Carlton); 2017 Jul; 22(7):548-554. PubMed ID: 27171136
[TBL] [Abstract][Full Text] [Related]
19. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
20. Is hepcidin-25 a clinically relevant parameter for the iron status in hemodialysis patients?
Brătescu LO; Bârsan L; Munteanu D; Stancu S; Mircescu G
J Ren Nutr; 2010 Sep; 20(5 Suppl):S77-83. PubMed ID: 20797577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
